LGND LIGAND PHARMACEUTICALS INC
FY2025 10-K
LIGAND PHARMACEUTICALS INC (LGND) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: biopharmaceutical royalty company focused on capital deployment and licensing for diversified royalty streams from mid- to late-stage products
- • New emphasis on NITRICIL platform acquired via Novan in 2023, supporting multiple royalty-bearing products including FDA-approved Zelsuvmi
Management Discussion & Analysis
- • Revenue and profit details not provided in the excerpt
- • No segment performance data disclosed in the excerpt
Risk Factors
- • Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate
- • Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year
Financial SummaryXBRL
Revenue
$268M
Net Income
$124M
Operating Margin
15.3%
Net Margin
46.4%
ROE
12.2%
Total Assets
$1.6B
EPS (Diluted)
$6.13
Operating Cash Flow
$49M
Source: XBRL data from LIGAND PHARMACEUTICALS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on LIGAND PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.